Fred Alger Management LLC grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 29.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 398,554 shares of the biotechnology company's stock after buying an additional 90,831 shares during the quarter. Fred Alger Management LLC owned 0.71% of Repligen worth $59,313,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Andra AP fonden purchased a new stake in shares of Repligen in the second quarter valued at about $25,000. International Assets Investment Management LLC purchased a new stake in Repligen in the 2nd quarter valued at approximately $33,000. UMB Bank n.a. grew its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC increased its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after buying an additional 136 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 127 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Trading Up 0.4 %
Shares of NASDAQ RGEN traded up $0.55 during midday trading on Friday, hitting $150.54. The stock had a trading volume of 225,812 shares, compared to its average volume of 664,788. The company has a fifty day moving average price of $140.98 and a 200 day moving average price of $142.85. The company has a market capitalization of $8.43 billion, a price-to-earnings ratio of -406.86, a PEG ratio of 4.52 and a beta of 0.96. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.23 earnings per share. On average, analysts predict that Repligen Co. will post 1.52 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on RGEN. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price for the company. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. Benchmark reaffirmed a "hold" rating on shares of Repligen in a research report on Monday, August 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $190.25.
Check Out Our Latest Research Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
